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Teriflunomide is a once-daily, oral disease-modifying therapy (DMT) for relapsing forms of
multiple sclerosis (MS). We studied clinical outcomes in a real-world setting involving a pop-
ulation-based large cohort of unselected patients enrolled in The Danish Multiple Sclerosis
Registry (DMSR) who started teriflunomide treatment between 2013–2019.
Methods
This was a complete nationwide population-based cohort study with prospectively enrolled
unselected cases. Demographic and disease-specific patient parameters related to treat-
ment history, efficacy outcomes, and discontinuation and switching rates among other clini-
cal variables were assessed at baseline and during follow-up visits.
Results
A total of 3239 patients (65.4% female) started treatment with teriflunomide during the study
period, 56% of whom were treatment-naïve. Compared to previously treated patients, treat-
ment-naïve patients were older on average at disease onset, had a shorter disease dura-
tion, a lower Expanded Disability Status Scale score at teriflunomide treatment start and
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more frequently experienced a relapse in the 12 months prior to teriflunomide initiation. In
the 3001 patients initiating teriflunomide treatment at least 12 months before the cut-off
date, 72.7% were still on treatment one year after treatment start. Discontinuations in the
first year were due mainly to adverse events (15.6%). Over the full follow-up period, 47.5%
of patients discontinued teriflunomide treatment. Sixty-three percent of the patients treated
with teriflunomide for 5 years were relapse-free, while significantly more treatment-naïve
versus previously treated patients experienced a relapse during the follow-up (p<0.0001).
Furthermore, 85% of the patients with available data were free of disability worsening at the
end of follow-up.
Conclusions
Solid efficacy and treatment persistence data consistent with other real-world studies were
obtained over the treatment period. Treatment outcomes in this real-world scenario of the
population-based cohort support previous findings that teriflunomide is an effective and gen-
erally well-tolerated DMT for relapsing MS patients with mild to moderate disease activity.
Introduction
Teriflunomide (Aubagio1) 14 mg is a once-daily, oral disease-modifying therapy (DMT)
approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) [1] or relapsing
forms of multiple sclerosis (RMS) [2] in more than 80 countries. The immunomodulatory
function comprises blocking de novo pyrimidine synthesis, which is required for the rapid pro-
liferation of activated lymphocytes implicated in MS but preserves resting cell function via the
pyrimidine salvage pathway [3,4].
The phase 3 TEMSO and TOWER randomized clinical trials (RCTs) involving patients
with RRMS showed superiority of teriflunomide over placebo with regard to relapses and dis-
ability accumulation [5,6]. Teriflunomide was also found effective in reducing risk of patients
with a clinically isolated syndrome (CIS) to convert to MS [7]. Phase 3 and 4 studies with teri-
flunomide have shown improved MRI outcomes with respect to brain lesion and atrophy mea-
sures compared to placebo [5,8–10]. Overall, teriflunomide has shown consistent efficacy and
safety outcomes both in the pivotal trials and in long-term extension studies [9,11–13].
Real-world studies provide relevant information about MS in a clinical setting where the
treated MS patient population is unselected, and therefore may provide more generalizable
data than the highly selected populations in RCT’s [14]. To this end, both the European Medi-
cines Agency (EMA) and the US Food & Drug Administration (FDA) endorse the collection
of real-world data to answer questions that cannot be addressed in RCTs and/or to provide
ongoing benefit-risk analyses of approved DMTs throughout the product lifecycle [15,16]. A
growing number of observational studies of teriflunomide are being reported, including stud-
ies on patient-reported outcomes [17–21], MRI endpoints [22], compliance and persistence
[23], and pregnancy outcomes [24].
In the Nordic countries, teriflunomide is commonly prescribed as a first-line drug for MS
patients with mild to moderate disease activity. However, no unselected nationwide real-world
data on treatment patterns and outcomes in teriflunomide-treated RRMS patients from this
region have been reported. To this end, the Danish Multiple Sclerosis Registry (DMSR) sys-
tematically compiles pre- and on-treatment clinical data for all residents of Denmark who
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have been diagnosed with MS. The DMSR serves as a near-complete, highly practical, and
dynamic source of real-world clinical data from closely followed patients in Denmark receiv-
ing different DMTs [25–27].
Following approval in 2013 by EMA, teriflunomide became the most commonly used oral
DMT in Denmark, particularly in view of Danish treatment guidelines from “The Danish
Council for the Use of Expensive Hospital Medicines”, recommending the use of terifluno-
mide as the first choice DMT with moderate efficacy in eligible RRMS or CIS patients.
In this study, we present nationwide Danish data on treatment patterns and efficacy out-
comes, discontinuation and switching rates compiled in the DMSR for teriflunomide-treated
patients during a period encompassing nearly six years since teriflunomide became available
in Denmark. We also show demographic and clinical variables for this unselected, real-world
population-based patient cohort at treatment onset and longer-term follow-up.
Materials and methods
Registry and approvals
The DMSR, which was established in 1956, compiles prospectively collected data on a range of
pre- and on-treatment clinical parameters [28]. In Denmark, diagnostic and clinical manage-
ment of patients with MS is exclusively carried out by 13 MS clinics in public hospitals, these
being the only units that are authorized to prescribe and dispense DMTs. All treating clinics
report data online to the DMSR on all patients with CIS and MS. It is mandatory for treating
neurologists to enter MS cases into the DMSR as a condition for patients being eligible to
receive DMTs from public hospitals in Denmark. This data collection forms part of the routine
medical follow-up of patients. Notification starts when the disease is diagnosed, with patients
then monitored during treatment in line with scheduled clinical visits at regular intervals dur-
ing which clinical and paraclinical information is recorded. The Kurtzke Expanded Disability
Status score (EDSS) and Functional Systems Scores are reported at treatment initiation and at
scheduled visits thereafter, while discontinuation, side effects, treatment switching, and
relapses are recorded along with corresponding dates. Reasons for discontinuation or switch
are also specified.
Study-type, population, and patient assessments
This was a complete nationwide population-based longitudinal cohort study with prospec-
tively enrolled cases. Adult patients (�18 years) who were registered in the DMSR to com-
mence treatment with teriflunomide between October 1, 2013 (when teriflunomide was
authorized for use in Denmark) and the September 19, 2019 cut-off date were included in the
study. For patients who started teriflunomide treatment on multiple occasions during this
period, the date of the first treatment episode was retained as the point of reference.
Patient parameters assessed at the start of teriflunomide treatment, used as covariates in the
statistical analyses, were demographics (age, sex), and MS disease-specific data: diagnosis
(RRMS, CIS), disease duration (diagnosis and onset), number of relapses in the previous year,
annualized relapse rate (ARR) at teriflunomide treatment start that counts the number of
relapses in the year prior to teriflunomide treatment start. If time since disease onset is 1 year
or less, the relapse count is forced to be at least 1. Furthermore, EDSS (closest to the terifluno-
mide start date, but not more than three months before this date), and previous DMTs and
reason for their discontinuation.
After starting treatment with teriflunomide, patients were scheduled to make follow-up vis-
its to their neurologist three and six at months into their treatment and at six to twelve-month
intervals thereafter. On-treatment variables that were collected included the time from
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teriflunomide treatment onset until first relapse, treatment discontinuation or end-of-follow-
up. If teriflunomide treatment was discontinued in the study period, the reason for this was
recorded. EDSS was assessed at each visit. Disability worsening was confirmed if an increase in
EDSS score was sustained over two consecutive visits separated by at least 6 months. The
thresholds for confirmed disability worsening (CDW) were�1.5 EDSS points if EDSS at treat-
ment initiation was 0,�1 EDSS point if EDSS at treatment start was 1–5.5, and�0.5 EDSS
points if EDSS at treatment start was�6 [29].
Categorization of previously administered DMTs
For previously treated patients, the DMTs they received were categorized as ‘Moderate effi-
cacy’ (teriflunomide, interferon beta-1a IM., glatiramer acetate, interferon beta-1b, peginter-
feron beta-1a, interferon beta-1a SC., dimethyl fumarate) or ‘High efficacy’ (fingolimod,
alemtuzumab, rituximab, cladribine, mitoxantrone, ocrelizumab, natalizumab, ofatumumab,
daclizumab) [30].
Statistical analyses
Categorical variables are reported as frequencies (n) with percentages (%), while continuous
variables are reported as median with inter-quartile range (IQR) and mean ± standard devia-
tion (SD). Differences between male and female patients, between treatment-naïve and previ-
ously treated patients, and between the start years were tested with a chi-squared test for
categorical covariates and with a non-parametric Kruskal-Wallis test for continuous
covariates.
The incidence of relapse after teriflunomide treatment start was investigated using Kaplan-
Meier plots with a log-rank test for differing incidences between male and female patients and
between treatment-naïve and previously treated patients.
Discontinuations due to adverse events or the need for treatment escalation were investi-
gated with Aalen-Johansen cumulative incidence curves with a Gray test for differentiating
cumulative incidences between male and female patients and between treatment-naïve and
previously treated patients.
The effect of different covariates on the cumulative incidence rates for discontinuation due
to adverse events and escalation were further investigated with sub-distribution hazard ratios
(HRs) from Fine and Gray’s sub-distribution hazard model, both unadjusted for each of the
covariates, and multivariably adjusted for all of the covariates simultaneously.
Effects of the covariates on confirmed disability worsening were investigated with odds
ratios (ORs) from logistic regression models. Since sufficient follow-up is required, EDSS
worsening could not be determined for almost half of the cohort, particularly for those that
started teriflunomide treatment late in the study period. Hence, the patients for whom EDSS
worsening could be determined were weighted in the analysis with the inverse of the probabil-
ity of being in the data set; the latter was estimated from a multivariable logistic regression
model that included all covariates. Confidence intervals were adjusted for this weighting using
the method of generalized estimating equations (GEE). Analyses on EDSS worsening were per-
formed both in unadjusted form for each of the covariates, and multivariably adjusted for all
the covariates simultaneously.
Ethics statement
Non-interventional register-based studies neither require ethical approval nor patients written
informed consent in Denmark. In Denmark, registry data are kept at secured research servers
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Data sharing is not permitted according to Danish legislation. These data are, however, avail-
able on request by researchers meeting the criteria for access to confidential information.
Results
Demographics and disease characteristics of study population
Total cohort. Baseline clinical characteristics of the patient cohort are shown in Tables 1
and 2. In brief, a total of 3239 patients (65.4% female) were treated with teriflunomide during
the study period. The diagnosis was RRMS in 93.4% of patients and CIS in the remainder. The
median age of patients at disease onset was 34.2 years, while the median age at teriflunomide
start was 42.9 years. Disability levels were generally low, with 61.7% of patients having an
EDSS score�2 and the overall mean EDSS of the cohort being 2.13. The mean ARR at teriflu-
nomide start was 0.53. Fifty-six percent of patients had received no prior DMT (i.e., treat-
ment-naive patients). In patients previously treated with other DMTs, moderate efficacy
DMTs had been prescribed in 96.1% of the patients, while 3.9% of patients switched from high
efficacy DMTs to teriflunomide. The main reason for switching from a previous DMT to teri-
flunomide was adverse events (65.7%), whereas the remaining patients were switched due to
disease breakthrough (3.0%) or listed as not specified/other (31.3%).
Female versus male patients. The female subgroup had a significantly higher median age
(43.5 vs. 41.5 years; p<0.0001), a longer disease duration (5 vs. 4 years; p<0.0001) and higher
EDSS (2.18 vs. 2.03; p = 0.0119) at teriflunomide treatment start compared to males (Table 1).
Females were also more likely than males to have been treated with other DMTs before switch-
ing to teriflunomide (45.3% vs. 40.6%; p = 0.0107), or in other words, more males were treat-
ment-naïve.
Treatment-naive versus previously treated patients. Patients in the treatment-naïve
group tended to be older at disease onset than previously treated patients (36.0 vs. 32.3 years;
p<0.0001) but had a shorter disease duration (1 vs. 10 years; p<0.0001) (Table 2). EDSS at ter-
iflunomide treatment start was lower on average in treatment-naïve cases than for previously
treated patients (1.95 vs. 2.35; p<0.0001). There was also a higher percentage of patients in the
treatment-naive group who had at least one relapse in the 12 months prior to the initiation of
teriflunomide (69.7% vs. 16.3% p<0.0001).
Temporal changes in teriflunomide use and baseline patient characteristics
from 2013 to 2019
Patients and disease characteristics of subgroups classified according to the year of terifluno-
mide treatment start are summarised in S1 Table. Median ages at disease onset (p = 0.0963)
and teriflunomide start (p = 0.1494) for the 2013 to 2019 period remained comparable. Fig 1
shows that sex distribution (Fig 1A) and mean EDSS at teriflunomide treatment start (Fig 1B)
remained relatively stable over the study period. Not surprisingly, we observed a decrease in
disease duration at teriflunomide start and time since disease diagnosis over the study period,
with neurologists increasingly prescribing teriflunomide as their first-line choice for patients
(S1 Table). This coincided with an increase from 19% to 76% in the percentage of treatment-
naïve patients receiving teriflunomide (Fig 1C). Moreover, these trends were reflected in the
proportion of patients who had no relapse in the year prior to starting teriflunomide, which
decreased from 80.7% to 37.8% (Fig 1D), clearly indicating disease activity in treatment-naïve
patients in the year prior to being prescribed teriflunomide as their first DMT as distinct from
patients switching from other DMTs. It should be noted that the raw numbers of patients
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treated with teriflunomide declined steadily from 2016 onwards and that the data for 2013 and
2019 do not reflect full calendar years.
One-year follow-up
S2 Table summarises characteristics and risk factors associated with treatment discontinuation
due to adverse events and treatment escalation at 1-year for patients who initiated terifluno-
mide treatment at least 12 months before the cut-off date (n = 3001). Of these patients, 72.7%
were still on teriflunomide 12 months after commencing treatment. Discontinuations in the
first year were due mainly to adverse events (15.6%), while 7.8% underwent therapy escalation.
Covariates associated with discontinuations due to adverse events or the need to escalate treat-
ment were observed in relation to sex, age at onset, disease duration at teriflunomide treatment
start, time to diagnosis, number of previous treatments, EDSS at any DMT start, EDSS at teri-
flunomide treatment start, and ARR.
Probability of discontinuation due to adverse events. Men had 43% less probability of
discontinuing teriflunomide due to adverse events in the first year after treatment start
(p<0.0001; S2 Table). The risk of discontinuation due to adverse events was higher in the
Table 1. Characteristics of the study population at teriflunomide treatment start.
Total (n = 3239) Male (n = 1120) Female (n = 2119) p-value
Age at disease onset, median (IQR), mean (SD)� 34.2 (26.6; 41.4) 34.5 (10.1) 33.4 (26.1; 41.2) 34.2 (10.2) 34.6 (27.0; 41.5) 34.7 (10.0) 0.0659
Age at TFL start, median (IQR), mean (SD)� 42.9 (35.2; 50.1) 42.6 (10.7) 41.5 (32.8; 49.2) 41.2 (11.2) 43.5 (36.4; 50.5) 43.3 (10.4) <0.0001
Disease duration at TFL start, median (IQR), mean (SD)� 5 (1; 12) 7.55 (8.13) 4 (1; 11) 6.55 (7.38) 5 (1; 13) 8.08 (8.46) <0.0001
Time since diagnosis, median (IQR), mean (SD)� 1 (0; 7) 4.41 (6.34) 1 (0; 6) 3.81 (5.80) 1 (0; 8) 4.72 (6.58) 0.0006
Diagnosis, n (%) 0.1519
CIS 215 (6.6) 84 (7.5) 131 (6.2)
MS 3024 (93.4) 1036 (92.5) 1988 (93.8)
Treatment naive, n (%) 0.0107
Yes 1824 (56.3) 665 (59.4) 1159 (54.7)
No 1415 (43.7) 455 (40.6) 960 (45.3)
Previous treatment, n (%) 0.6197
Moderate efficacy DMT 1360 (96.1) 439 (96.5) 921 (95.9)
High efficacy DMT 55 (3.9) 16 (3.5) 39 (4.1)
Number of DMTs before TFL start, n (%) 0.0008
None 1824 (56.3) 665 (59.4) 1159 (54.7)
1 793 (24.5) 284 (25.4) 509 (24.0)
2 389 (12.0) 118 (10.5) 271 (12.8)
3 149 (4.6) 35 (3.1) 114 (5.4)
4 53 (1.6) 12 (1.1) 41 (1.9)
>4 31 (1.0) 6 (0.5) 25 (1.2)
EDSS at TFL start, median (IQR), mean (SD) 2.0 (1.0; 3.0) 2.13 (1.46) 2.0 (1.0; 2.5) 2.03 (1.43) 2.0 (1.0; 3.0) 2.18 (1.47) 0.0119
ARR in year prior to TFL start, median (IQR), mean (SD) 0 (0; 1) 0.53 (0.62) 0 (0; 1) 0.53 (0.59) 0 (0; 1) 0.53 (0.64) 0.3764
Number of relapses in year prior to TFL start, n (%) 0.1531
0 1736 (53.6) 581 (51.9) 1155 (54.5)
�1 1503 (46.4) 539 (48.1) 964 (45.5)
ARR: Annualized relapse rate, CIS: Clinically isolated syndrome, DMT: Disease-modifying therapy, EDSS: Expanded Disability Status Scale, IQR: Interquartile range,
MS: Multiple sclerosis, n: Number, SD: Standard deviation, TLF: Teriflunomide.
�in years.
https://doi.org/10.1371/journal.pone.0250820.t001
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previously treated group regardless of sex (HR: 1.51; 95% CI: 1.30–1.77), especially in those
previously treated with high efficacy DMTs (HR: 1.80; 95% CI: 1.15–2.83). Moreover, the risk
of discontinuation due to adverse events increased in line with an increasing number of previ-
ous treatments. After multivariate adjustment for risk factors, we found that men were 39%
less likely to discontinue due to adverse events (HR: 0.61; 95% CI: 0.50–0.74), and that a higher
number of previous DMTs was associated with an increased risk of discontinuation due to
adverse events.
Probability of escalation. Treatment escalation in the first year following teriflunomide
initiation was significantly higher in male patients (HR: 1.32; 95% CI: 1.13–1.55; S2 Table).
The previously treated patient group had a 43% lower risk for treatment escalation (HR: 0.57;
95% CI: 0.49–0.67) irrespective of the efficacy of previous drugs. The lower risk applied to
patients previously treated with one (HR: 0.57; 95% CI: 0.47–0.69) or two (HR: 0.52; 95% CI:
0.40–0.68) DMTs compared to treatment-naïve patients. A 10-year increase in age at disease
onset and in disease duration was associated with a 25% (p = 0.0001) and 37% (p = 0.0001),
respectively, lower likelihood of treatment escalation. Multivariably adjusted HRs confirmed
the increased probability of escalation in male patients (HR: 1.24; 95% CI: 1.05–1.46) as well as
the lower likelihood of escalation associated with a 10-year increase in age at disease onset and
in disease duration, and the number of previous DMTs.
Confirmed disability worsening
Table 3 summarises disability worsening outcomes for patients with available data (i.e.,
patients with at least 3 EDSS measurements spaced a minimum of 6 months apart) and com-
pares outcomes for 10-year differences in parameters such as age at disease onset, and age and
disease duration at teriflunomide treatment start among other parameters. CDW was observed
in 243 out of 1624 (15.0%) patients with available data. The probability of worsening was not
Table 2. Characteristics of the treatment naïve and previously treated subgroup at teriflunomide treatment start.
Total (n = 3239) Treatment naive (n = 1824) Previously treated (n = 1415) p-value
Sex, n (%) 0.0107
Male 1120 (34.6) 665 (36.5) 455 (32.2)
Female 2119 (65.4) 1159 (63.5) 960 (67.8)
Age at disease onset, median (IQR), mean (SD)� 34.2 (26.6; 41.4) 34.5 (10.1) 36.0 (28.1; 43.2) 36.1 (10.3) 32.3 (25.5; 39.1) 32.6 (9.5) <0.0001
Age at TFL start, median (IQR), mean (SD)� 42.9 (35.2; 50.1) 42.6 (10.7) 41.4 (32.9; 48.7) 40.8 (10.8) 44.9 (38.4; 51.8) 44.9 (10.1) <0.0001
Disease duration at TFL start, median (IQR), mean (SD)� 5 (1; 12) 7.55 (8.13) 1 (0; 5) 4.24 (6.58) 10 (6; 17) 11.80 (7.96) <0.0001
Time since diagnosis, median (IQR), mean (SD)� 1 (0; 7) 4.41 (6.34) 0 (0; 0) 1.08 (3.63) 7 (3; 13) 8.70 (6.50) <0.0001
Diagnosis, n (%) <0.0001
CIS 215 (6.6) 164 (9.0) 51 (3.6)
MS 3024 (93.4) 1660 (91.0) 1364 (96.4)
EDSS at TFL start, median (IQR), mean (SD) 2.0 (1.0; 3.0) 2.13 (1.46) 2.0 (1.0; 2.5) 1.95 (1.26) 2.0 (1.5; 3.0) 2.35 (1.65) <0.0001
ARR in year prior to TFL start, median (IQR),
mean (SD)
0 (0; 1) 0.53 (0.62) 1 (0; 1) 0.79 (0.61) 0 (0; 0) 0.19 (0.46) <0.0001
Number of relapses in year prior to TFL start, n (%) <0.0001
0 1736 (53.6) 552 (30.3) 1184 (83.7)
�1 1503 (46.4) 1272 (69.7) 231 (16.3)
ARR: Annualized relapse rate, CIS: Clinically isolated syndrome, DMT: Disease-modifying therapy, EDSS: Expanded Disability Status Scale, IQR: Interquartile range,
MS: Multiple sclerosis, n: Number, SD: Standard deviation, TLF: Teriflunomide.
�in years.
https://doi.org/10.1371/journal.pone.0250820.t002
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affected by sex (OR: 0.93; 95% CI: 0.66–1.31). We observed a 30% higher risk of CDW with a
10-year increase in age at disease onset, and a 39% higher risk for a 10-year increase in age at
teriflunomide treatment start. Multivariably adjusted ORs showed an increased risk for CDW
of 54% for a 10-year increase in age at disease onset (OR: 1.54; 95% CI: 1.29–1.85), and a 45%
increased risk for a 10-year increase in disease duration (OR: 1.45; 95% CI: 1.14–1.85) at teri-
flunomide treatment start. There was no longer a significant difference in the risk of disability
worsening between the treatment-naïve and previously treated groups when the multivariate
test was used to calculate adjusted ORs. However, previous treatment with a high-efficacy
DMT was linked to an increased risk of EDSS worsening (OR: 5.11; 95% CI: 1.47–17.82).
Follow-up for the 2013 to 2019 treatment period
The mean teriflunomide treatment duration until the data cut-off date was 2.18 ± 1.65 years
(range: 0.00–5.77 years). Sixty-three percent of the patients who had been treated with teriflu-
nomide for 5 years were relapse-free (Fig 2A), with no sex-associated differences observed for
this parameter (Fig 2B). Significantly more treatment-naïve patients experienced a relapse dur-
ing the follow-up (p<0.0001; Fig 2C). At the same time, 85% of the patients with available data
were free of CDW. Stratification for sex showed no difference, while previously treated
Fig 1. Baseline characteristics of patients starting teriflunomide treatment between 2013–2019 in Denmark. (A) Frequency and
distribution of female (red) and male (blue) patients starting teriflunomide each year. The blue dots denote the percentage of male patients of
the total teriflunomide patient starts each year (B) EDSS at teriflunomide start. The red dots show the mean EDSS, whereas the blue boxes show
the median (IQR) EDSS per year. (C) Frequency and distribution of treatment-naïve (blue) and previously treated (red) patients starting
teriflunomide each year. The blue dots denote the percentage of treatment-naïve patients of the total teriflunomide patient starts each year. (D)
Frequency and distribution of patients with an annualized relapse rate (ARR) of 0 (blue) and ARR>0 (red) in the year prior to teriflunomide
start. The blue dots denote the percentage of patients with an ARR of 0 out of the total teriflunomide patient starts each year. Note, that
teriflunomide received marketing authorization in October 2013 and the cut-off for data collection was September 2019, therefore patient
numbers in 2013 and 2019 (dotted boxes) are based on data from approximately 3 and 9 months, respectively.
https://doi.org/10.1371/journal.pone.0250820.g001
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patients had a higher risk of developing CDW compared to treatment-naïve patients (Fig 2D–
2F). Cumulative incidence plots show that risk of discontinuation of teriflunomide was highest
within the first year due to adverse events associated with treatment initiation (Fig 2G–2I),
with the curve tending to flatten out after this time. The risk of discontinuation due to an
adverse event was significantly higher in females versus males (Fig 2H) and in previously
Table 3. Confirmed disability worsening.
Confirmed disability worsening Unadjusted Adjusted§
No Yes OR (95%CI) p-value OR (95%CI) p-value
(n = 1381) (n = 243)
Sex, n (%)
Male 521 (86.0) 85 (14.0) 0.95 (0.68–
1.33)
0.7550 1.02 (0.71–1.46) 0.9296
Female 860 (84.5) 158 (15.5) ref ref
Age at disease onset, median (IQR), mean (SD)� 34.4 (27.0; 41.6) 34.8
(10.1)




0.0012 1.54 (1.29–1.85) <0.0001
Age at TFL start, median (IQR), mean (SD)� 43.3 (36.0; 50.5) 43.2
(10.3)





Disease duration at TFL start, median (IQR), mean
(SD)�
5 (1; 12) 7.88 (8.04) 6 (2; 14) 8.82 (8.64) 1.13 (0.95–
1.34)
0.1665 1.45 (1.14–1.85) 0.0026
Disease duration at TFL start
0 years 169 (87.1) 25 (12.9) ref ref
>0 years 1211 (84.7) 218 (15.3) 1.30 (0.72–
2.20)
0.4180 0.96 (0.49–1.89) 0.9149
Time since diagnosis, median (IQR), mean (SD)� 1 (0; 7) 4.50 (6.16) 2 (0; 9) 5.34 (7.14) 1.19 (0.96–
1.49)
0.1197 1.03 (0.69–1.56) 0.8708
Time since diagnosis
0 years 572 (87.3) 83 (12.7) ref ref
>0 years 809 (83.5) 160 (16.5) 1.33 (0.95–
1.85)
0.0963 1.14 (0.74–1.76) 0.5444
Diagnosis
CIS 91 (85.9) 15 (14.1) 0.90 (0.48–
1.67)
0.7379 0.86 (0.42–1.80) 0.6972
MS 1290 (85.0) 228 (15.0) ref ref
Treatment naive
Yes 724 (86.7) 111 (13.3) ref ref
No 657 (83.3) 132 (16.7) 1.41 (1.03–
1.93)
0.0346 1.36 (0.80–2.30) 0.2580
Previous treatment
Moderate efficacy DMT 642 (83.8) 124 (16.2) ref ref





EDSS at TFL start 2 (1.5; 3) 2.14 (1.43) 2 (1; 2.5) 2.04 (1.67) 0.92 (0.82-1-
02)
0.1074 0.82 (0.73–0.93) 0.0014
Number of relapses in year prior to TFL start, n (%)
0 796 (83.9) 153 (16.1) ref ref
�1 585 (86.7) 90 (13.3) 0.76 (0.55–
1.06)
0.1035 0.87 (0.60–1.28) 0.4720
CIS: Clinically isolated syndrome, DMT: Disease-modifying therapy, EDSS: Expanded Disability Status Scale, IQR: Interquartile range, MS: Multiple sclerosis, n:
Number, OR: Odds ratio, SD: Standard deviation, TLF: Teriflunomide.
�10-year. §OR adjusted for sex, age at disease onset, time since diagnosis, treatment naïve, EDSS at TFL start and number of relapses in the year prior to TFL start.
https://doi.org/10.1371/journal.pone.0250820.t003
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treated patients versus treatment-naïve patients (Fig 2I). The cumulative incidence of disease
breakthrough-related discontinuation increased throughout the follow-up period and was sig-
nificantly greater in males (p = 0.0006, and in treatment naïve (p<0.0001) patients (Fig 2J–2L)
who were also younger at teriflunomide start.
Teriflunomide discontinuations and treatment switches
Over the course of the follow-up period, 1538 of the 3239 registered patients (47.5%) discon-
tinued teriflunomide treatment, the main reasons for which were side effects (41.9%) and dis-
ease breakthrough (42.7%). Of the discontinuing patients, 1304 (84.8%) switched to any one of
several different DMTs (Table 4). Fifty-three percent of switches were to a high efficacy DMT
and 46.3% did a lateral switch to another moderate efficacy DMT. Fifty-two patients re-started
on teriflunomide treatment after initial discontinuation. At the final cut-off date for the study,
234 patients (15.2%) who discontinued teriflunomide treatment had not switched to another
DMT.
Fig 2. Long-term follow-up of patient started on teriflunomide between 2013 and 2019. Percentage of relapse-free
patients in the whole cohort (A) during the follow-up, stratified by sex (B) and history of previous treatment (C).
Percentage of patients free of 6-months confirmed disability worsening (CWD) in the whole cohort (D) during the
follow-up, stratified by sex (E) and history of previous treatment (F). There were no male patients registered with
relapse or CDW after 4.5 years, therefore the curves are shorter for males than females in B and E. Cumulative
incidence of discontinuation due to adverse events in the whole cohort (G), stratified by sex (H) and history of
previous treatment (I). Cumulative incidence of discontinuation due to disease breakthrough in the whole cohort (J),
stratified by sex (K) and history of previous treatment (L).
https://doi.org/10.1371/journal.pone.0250820.g002
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Discussion
This complete nationwide unselected population-based cohort study provides insights into the
real-world use and efficacy of oral teriflunomide for the treatment of RRMS patients in Den-
mark between 2013–2019. Studies of this type involving the systematic compilation of pre-
and on-treatment clinical data for all MS patients in a specific country will enable healthcare
providers to offer better-informed opinions to their patients concerning treatment options in
a real-world clinical setting. In this way, the utility of structured registries such as the DMSR
will become more apparent as data analytics reveal to patients, physicians and healthcare
authorities the potential benefits and shortfalls of different DMTs within an expanding
armamentarium.
More than 3200 patients received teriflunomide during this nearly six-year period over
which DMSR data for this study were compiled, a scenario driven in part by guidelines from
“The Danish Council for the Use of Expensive Hospital Medicines”, recommending the use of
Table 4. Teriflunomide discontinuations and treatment switches during the study period (2013–2019).
Patients
(n = 3239)
Was teriflunomide treatment discontinued before the end of follow-up? n (%)
No 1701 (52.5)
Yes 1538 (47.5)
Because of side effects 645 (41.9)
Because of disease breakthrough 658 (42.7)
Because of death 7 (0.4)
Because of pregnancy 49 (3.2)
Because of other/unknown reasons 181 (11.8)
Which drugs did discontinuing patients switch to?
Did not switch to any DMT, n (%) 234 (15.2)
Switched to another DMT, n (%) 1304 (84.8)
Switched to moderate efficacy DMT, n (%) 604 (46.3)
Dimethyl fumarate 401 (30.8)
Glatiramer acetate 68 (5.2)
Teriflunomide� 52 (4.0)
Peginterferon beta-1 43 (3.3)
Interferon beta-1a im. 30 (2.3)
Interferon beta-1a sc. 10 (0.8)










DMT: Disease-modifying treatment, im: Intramuscular, sc: Subcutaneous.
�these patients re-started teriflunomide treatment after initial discontinuation for various reasons.
https://doi.org/10.1371/journal.pone.0250820.t004
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teriflunomide as a first-line choice for at least 95% of eligible RRMS and CIS patients with
moderate disease activity, except in women planning pregnancy within a year. Demographic
characteristics showed that this real-world cohort had mild to moderate disease activity as
indicated by pre-existing relapse activity and EDSS scores, and was older on average than
patient cohorts in the phase 3, placebo-controlled TEMSO, TOWER and TOPIC clinical trials,
an observation that is consistent with age distributions in other real-world studies with teriflu-
nomide [18,20]. Interestingly, the female population in this cohort had a significantly higher
median age than the male population. This could be due to the willingness of women who no
longer wish to have children to switch to teriflunomide in observance of guidelines advising
against the prescribing of teriflunomide to women of childbearing age intending to become
pregnant within the next year.
The first three years of the DMSR study (2013–2016) (Fig 1) provide an interesting over-
view of the dynamics of treatment practices following teriflunomide’s approval and subsequent
recommendations by “The Danish Council for the Use of Expensive Hospital Medicines”, for
its first-line use in RRMS and CIS patients. This was clearly borne out in data showing that the
proportion of treatment-naïve patients was low early in the study period, hence indicating that
most of the patients receiving teriflunomide were switching from other DMTs (Fig 1). To this
end, the Teri-PRO study [18] provides an explanation for this trend towards teriflunomide
treatment uptake, with patients in that study who switched to teriflunomide from other DMTs
reporting improved treatment satisfaction versus baseline after 48 weeks of teriflunomide
treatment. The percentage of treatment-naïve versus previously treated patients increased pro-
gressively in the first two years of our study, reaching a steady level around 75% (Fig 1C).
Indeed, around 400 treatment-naïve MS patients out of around 600 patients newly diagnosed
with MS in Denmark each year started teriflunomide as guidelines and practices resulted in an
increased first choice use of teriflunomide in eligible patients. Balanced against these findings
was a decrease in the raw number of previously treated patients in the overall cohort as the
study advanced, the main reason for this being that most of the eligible patients had already
switched from injectable therapies to teriflunomide in the first years after marketing
authorization.
Concerning efficacy outcomes, a reduction over time in the percentage of patients with no
relapse activity in the 12 months prior to study entry (Fig 1D) reflected the fact that new
patients coming into the study were treatment-naïve and had relapse activity, thus explaining
why they were started on teriflunomide. Nevertheless, the fact that 72.7% of patients were still
on teriflunomide 12 months after starting treatment, and that more than 50% of patients
remained on teriflunomide at the end of the study period indicates that, despite relatively high
percentages of patients coming into the study with prior relapse activity, good disease control
in the overall cohort was subsequently achieved. The higher discontinuation rate due to disease
breakthrough in treatment-naïve versus previously treated patients (Fig 2L) suggests that some
of those patients did not achieve a desired level of disease control. This is not surprising as
treatment-naïve patients were 4 years younger on average at teriflunomide start and therefore
likely more prone to neuroinflammation [31]. One can speculate that most previously treated
patients likely switched to teriflunomide due to adverse events or convenience due to the
administration mode, as patients experiencing disease breakthrough on their previous DMT
would have been escalated to a high-efficacy DMT instead of teriflunomide. Indeed, this is
reflected in the fact that more than half of all patients who switched to another DMT after dis-
continuing teriflunomide escalated to DMTs with high efficacy (Table 4). Furthermore, the
significantly higher cumulative incidence of disease breakthrough-related discontinuation
seen in males versus females (Fig 2K) is consistent with previous observations of more aggres-
sive disease in males [32].
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In relation to disability worsening, 85% of patients were free of CDW and the multivariate
analysis showed that there was no significant difference in the risk of CDW between the treat-
ment-naïve and previously treated patients who remained on teriflunomide treatment during
the study. However, older patients with a longer disease duration did have a higher risk of
CDW. Given these time-related differences, and the fact that many patients in this real-world
cohort were over 40 years of age at teriflunomide initiation, it is likely that some of these
patients were in transition into a secondary progressive stage of the disease.
Findings in a recently published real-world study by Vermersch et al. (2020) concerning
outcomes from a French nationwide health claims database for the 2014–2017 period support
several of the observations that we report here. Based on an RRMS cohort of over 10,000 treat-
ment-naïve patients started on different moderate efficacy DMTs, patients treated with teriflu-
nomide (n = 3548) had similar baseline characteristics to those in our study, and showed a
persistence rate of nearly 60% at 24 months after treatment start. Of those patients who discon-
tinued teriflunomide treatment, nearly 50% switched to a high efficacy DMT, indicating a
need for more aggressive treatment approach to provide sufficient disease control as we have
shown [23]. The 15.2% of patients who discontinued teriflunomide treatment, but had not
switched to another DMT at the cut-off date, could be either patients still in the wash-out
period before treatment switch, patients in transition to secondary progressive MS and/or
patients that decided to terminate any DMT treatment.
Like any real-world investigation, the study also has some limitations. Despite this being a
near-complete registry, there are missing follow-up data. This would nevertheless be low since
it is mandatory to report patient data in the DMSR in order to prescribe DMTs to MS patients
at public hospitals, and treatments for MS are exclusively provided by the public hospitals’ MS
clinics. Furthermore, indication bias cannot be excluded, as the 2017 McDonald revision
made earlier diagnosis and treatment start possible [33]. Additionally, even though MRI data
are not included in this DMSR study, significant disease activity on MRI images would have
been treated as disease breakthrough and triggered escalation to a higher efficacy DMT.
Despite the study’s limitations, the results described here provide important insights into the
implementation and experience of teriflunomide as a first-line treatment for RRMS and CIS in
a large, nationwide cohort from Denmark, and may provide guidance on which patients are
likely to benefit from this drug when variables such as age, sex, prior treatments and disease
activity are taken into account.
This study provides a window into teriflunomide treatment patterns and clinical outcomes
in Denmark over an extended period of nearly six years from the time teriflunomide became
available in October 2013. Importantly, the study provides timely and meaningful information
about teriflunomide use in an unselected, real-world Danish MS cohort of more than 3200
patients. During this period, solid efficacy and treatment persistence data consistent with
other real-world studies were obtained. Our analysis of treatment outcomes in this real-world
clinical environment support previous findings that teriflunomide is an effective and generally
well-tolerated DMT for RRMS patients with mild to moderate disease activity.
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